Skip to content
Open access · OA via OpenAlex

Targeting the LKB1 Tumor Suppressor

Rui–Xun Zhao, Zhi‐Xiang Xu

Current Drug Targets · 2014 · ▲ 60 citations

Abstract

LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies and challenges in targeting LKB1 inactivation are also considered.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.2174/1389450114666140106095811
Canonical
link ↗
Fetched
2026-06-01 MST

Cite this

APA
Zhao, R., &amp; Xu, Z. (2014). Targeting the LKB1 Tumor Suppressor. <em>Current Drug Targets</em>. https://doi.org/10.2174/1389450114666140106095811
Vancouver
Zhao R, Xu Z. Targeting the LKB1 Tumor Suppressor. Current Drug Targets. 2014. doi:10.2174/1389450114666140106095811.
BibTeX
@article{ruixun2014Target, title = {Targeting the LKB1 Tumor Suppressor}, author = {Rui–Xun Zhao and Zhi‐Xiang Xu}, journal = {Current Drug Targets}, year = {2014}, doi = {10.2174/1389450114666140106095811}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings